Life sciences and medtech companies raise against regulatory and clinical milestones rather than revenue, which means the round has to be sized to a milestone the company can actually reach with the money. Zenith runs fundraise readiness for clinical-stage and commercial-stage companies — data rooms, diligence trackers, financial models and parallel non-dilutive workstreams — from seed through Series B.
A clearance, a trial readout, or a reimbursement decision moves on a regulatory calendar the company doesn't control. Cash moves on a burn schedule it does. Almost every difficult raise in this sector traces back to those two calendars being out of phase — the company needs money six months before the milestone that would have priced the round properly.
The practical consequence is that the financing plan has to be built backwards from the milestone, with the bridge to it explicitly funded, rather than forwards from the current burn.
This is most acute in placed-instrument businesses — analysers deployed into clinics generating recurring consumable revenue. The revenue model shows a convincing curve. The cash model shows something else: instrument capex funded ahead of the revenue it generates, a receivables build tracking the ramp, and one-time regulatory spend that lands in the same period.
Stack those three and a business growing several-fold on paper can run out of money. Companies raise on the revenue model and fail on the cash model, and the gap between them is usually discovered mid-process rather than before it.
Early-stage diagnostics and therapeutics companies frequently pitch a platform — several indications, several applications, an ambitious total addressable market. Investors respond by trying to work out which company they're being asked to fund.
Most seed rounds that stall aren't underpriced; they're under-specified. Narrowing to a single lead indication and sizing the raise to a defined milestone rather than to the roadmap is usually the fastest path to a term sheet, and it is a positioning decision rather than a financial one.
Companies with cleared products and contracted revenue frequently have a working capital requirement that is better served by debt than by equity — venture debt, revenue-based structures, or royalty financing depending on the asset.
Running that conversation alongside the equity process changes the equity negotiation, because the company is no longer solving its entire requirement with one instrument. Run sequentially, it changes nothing, because by the time the debt conversation starts the round is already priced.
Royalty, revenue-interest and venture-debt structures for companies with approved products or contracted milestones, where equity at the current mark is the expensive option.
Runway, grant and milestone accounting, and a board pack that survives a diligence pass — for science teams where the finance function has not yet caught up with the raise.
Separating funded research from commercial earnings, defending grant and milestone recognition, and building a data room a strategic acquirer's team can work through unassisted.
Science-led companies rarely need advice; they need someone commercially accountable inside the team. The operator carries a named outcome and hands over to a permanent hire.
Translating a technical programme into a financeable plan: milestone-linked use of proceeds, dilution scenarios, and a data room that answers the second question as well as the first.
USD 45,000,000
pre-money valuation
Rebuilding the finance function underneath a Series A extension
Equity round with a parallel non-dilutive debt workstream
Resizing a seed round from the roadmap to the milestone
103-item diligence tracker, data room build, and a resized seed raise following indication prioritisation
Finding the cash wall the growth model concealed
Pre-raise financial review — identified a projected cash shortfall in the out-year driven by regulatory spend, receivables build and instrument capex stacking in one period
Enough to reach a specific regulatory or clinical milestone with a funded bridge, not enough to cover the roadmap. Sizing the round backwards from the milestone — rather than forwards from current burn — avoids raising into a gap where cash runs out six months before the event that would have priced the next round properly. Narrowing to a single lead indication, rather than pitching a platform, is usually what makes the number defensible to investors.
Clinical and regulatory documentation mapped against the milestone timeline, a financial model that separates revenue projections from an actual cash model, and evidence supporting the narrowed indication being pitched. For placed-instrument businesses, this includes instrument capex schedules and receivables build alongside the consumable revenue curve, since the revenue model and the cash model routinely answer different questions.
Once the product is cleared and generating contracted revenue, a working capital requirement is often better served by venture debt, revenue-based financing or royalty structures than by further dilution. The value is greatest when that conversation runs in parallel with an equity process, since it changes the equity negotiation; run afterwards, once the round is priced, it changes nothing.
A data room stores documents; a diligence tracker manages the live process of investor questions, follow-ups and outstanding items across parallel workstreams. It keeps the regulatory-milestone and cash-burn calendars visible against each other, and surfaces gaps — such as an under-modelled receivables build — before an investor finds them mid-process rather than during it.
Largely on the credibility of the path to the milestone rather than current revenue: the strength of the clinical data, the specificity of the regulatory strategy, and whether the raise is sized to reach clearance with a funded bridge rather than run out before it. A narrowed, well-evidenced single indication prices more predictably than a broad platform story with an ambitious total addressable market.
Last reviewed August 2026
Tell us the transaction and the timetable. If it is not something we should run, we will say so.
